Results 281 to 290 of about 659,851 (390)

Current treatment of in-stent restenosis.

open access: yesJournal of the American College of Cardiology, 2014
F. Alfonso   +3 more
semanticscholar   +1 more source

Angiographic ‘haziness’ following stent deployment: Differential diagnosis using intravascular ultrasound

open access: bronze, 1996
Khaled M. Ziada   +8 more
openalex   +1 more source

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT‐ACS Emulation Using National Health Insurance Claims Data

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang   +6 more
wiley   +1 more source

Intermediate Outcomes in the Prospective, Multicenter Coarctation of the Aorta Stent Trial (COAST)

open access: yesCirculation, 2015
Jeffery Meadows   +4 more
semanticscholar   +1 more source

Clinical impact of tricuspid regurgitation in patients with acute myocardial infarction

open access: yesESC Heart Failure, EarlyView.
Abstract Aims The clinical impact of tricuspid regurgitation (TR) in patients after acute myocardial infarction (AMI) is largely unknown. The aim of this study was to clarify the prevalence and prognostic impact of TR in post‐AMI patients treated with appropriate primary percutaneous coronary intervention (PCI).
Shun Nishino   +5 more
wiley   +1 more source

Transcatheter Coronary Artery Bypass to Circumvent Iatrogenic Obstruction: The VECTOR (Ventriculo-Coronary Transcatheter Outward Navigation and Re-Entry) Procedure in Swine. [PDF]

open access: yesCirc Cardiovasc Interv
Bruce CG   +7 more
europepmc   +1 more source

DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT‐HF): Baseline characteristics compared to recent randomized controlled heart failure trials

open access: yesEuropean Journal of Heart Failure, EarlyView.
Effects of digitoxin compared to placebo on efficacy and safety in patients with heart failure and reduced ejection fraction (HFrEF). Primary endpoint: time to all‐cause death and first hospitalization for worsening heart failure (whatever occurs first). ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin
Udo Bavendiek   +35 more
wiley   +1 more source

Home - About - Disclaimer - Privacy